BioCentury
ARTICLE | Financial News

Pharmacyclics plunges on failed Phase III

December 14, 2001 8:00 AM UTC

PCYC was off $12.31 (57%) to $9.39 on Friday. On Thursday just before market close, the company said that in an international Phase III trial in 401 patients with brain metastases, the combination of ...